HQH Abrdn Healthcare Investors
USFinancial ServicesAs of 2026-08-24
Why HQH matters now
Abrdn Healthcare Investors (HQH) is a US stock in Financial Services. The latest InvestLog snapshot shows $23.37 with -4.18% on the session and $1.34B in market capitalization; recent performance reads 1-month +2.91% and YTD +6.60%.
The latest financial table shown here is FY 2025, with revenue of $99.8M, net income of $98.6M, and EPS of $1.84. Investors can compare that operating picture with valuation signals such as P/E 10.31 and FCF yield 0.8%.
The latest indexable market news headline is "Opportunity To Catch 2 Income Picks Before Their Yield Goes Higher" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is available with a median target of $—; recent insider activity includes Mahai Chris LaVictoire filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
10.31
PEG
0.01
P/B
1.01
P/S
51.34
EV/EBITDA
6.66
DCF Value
$13.59
FCF Yield
0.8%
Div Yield
11.5%
Margins & Returns
Gross Margin
77.2%
Operating Margin
770.3%
Net Margin
1150.1%
ROE
24.0%
ROA
23.6%
ROIC
15.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| FY 2025 | $99.8M | $98.6M | $1.84 |
| Q4 2025 | $17.0M | $173.4M | $3.17 |
| FY 2025 | $99.8M | $98.6M | $1.84 |
| Q4 2024 | $5.5M | $85.2M | $1.59 |
Analyst Ratings
Consensus
—
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Financial Services
Industry
Asset Management
Country
US
Exchange
—
Beta
0.76
Abrdn Healthcare Investors is a closed-end equity fund, stewarded by abrdn Inc. Its mandate involves global public equity investments, specifically targeting the healthcare sector, encompassing businesses in biotechnology, medical devices, and pharmaceuticals. The primary focus is on high-growth, small-capitalization companies. The portfolio is constructed using a fundamental analysis approach, scrutinizing companies based on their current or projected market position for products and services, the experience of their management teams, their technological prowess, and their capability to either self-fund growth or secure external financing. Its performance is measured against several benchmarks: the NASDAQ Biotechnology Index, the S&P 500 Index, and the S&P 1500 Healthcare Index. Established on October 31, 1986, the fund is domiciled in the United States.